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Abstract
Background: Increased levels of cortisol during acute alcohol withdrawal have been linked to cognitive deficits and
depression. Preclinical research found that the glucocorticoid Type II receptor antagonist, mifepristone, prevented
some of the neurotoxic effects of withdrawal and memory loss. Clinical trials have shown mifepristone effective in the
treatment of depression. This study aims to examine the extent to which the glucocorticoid Type II receptor
antagonist, mifepristone, when given to alcohol dependent males during the acute phase of alcohol withdrawal,
will protect against the subsequent memory loss and depressive symptoms during abstinence from alcohol.
Methods/Design: The study is a Phase 4 therapeutic use, “Proof of Concept” trial. The trial is a double-blind randomised
controlled clinical trial of mifepristone versus inactive placebo. The trial aims to recruit 120 participants referred for an
inpatient alcohol detoxification from community alcohol teams, who meet the inclusion criteria; 1) Male, 2) Aged 18–60
inclusive, 3) alcohol dependent for 5 or more years. A screening appointment will take place prior to admission to
inpatient alcohol treatment units to ensure that the individual is suitable for inclusion in the trial in accordance with the
inclusion and exclusion criteria. On admission participants are randomised to receive 600 mg a day of mifepristone
(200 mg morning, afternoon and evening) for 7 days and 400 mg for the subsequent 7 days (200 mg morning and
evening) or the equivalent number of placebo tablets for 14 days. Participants will remain in the trial for 4 weeks (at least
2 weeks as an inpatient) and will be followed up at 3, 6 and 12 months post randomisation. Primary outcome measures
are cognitive function at week 3 and 4 after cessation of drinking and symptoms of depression over the 4 weeks after
cession of drinking, measured using the Cambridge Neuropsychological Test Automated battery and Beck Depression
Inventory, respectively. Secondary outcome measures are severity of the acute phase of alcohol withdrawal, alcohol
craving, symptoms of protracted withdrawal and maintenance of abstinence and levels of relapse drinking at follow-up.
Discussion: The current trial will provide evidence concerning the role of glucocorticoid Type II receptor activation in
cognitive function and depression during acute alcohol withdrawal and the efficacy of treatment with mifepristone.
Trial registration: ISRCTN: ISRCTN54001953, Registered 29th September 2011.
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Background
Cognitive deficits are seen in 50 to 80 % of those
dependent on alcohol [1] currently there is no effect-
ive treatment. The cognitive functions particularly
affected in alcohol dependence are learning new skills,
visuospatial ability, executive function (planning,
capacity for abstraction and effortful processing), and
aspects of attention, whilst verbal skills usually remain
intact [2–6]. The cognitive deficits not only affect the
quality of life of those dependent on alcohol and the
amount of health care they need, but also have a
detrimental effect on ability to benefit from treatment
programmes [4, 7, 8]. Depression is a major symptom
in many people who are dependent on alcohol, and is
associated with greater tendency to relapse drinking
[9]. Most depressive symptoms in this population are
secondary to the alcohol dependence and gradually
resolve spontaneously. Despite this, improvement in
symptomatology could provide faster and more
complete recovery and would aid abstinence.
The majority of those dependent on alcohol
undergo frequent episodes of withdrawal and resump-
tion of drinking, and clinical evidence indicates that
“kindling” occurs, as a higher number of withdrawal
episodes are associated with greater severity of with-
drawal, including greater memory impairment [10].
Schandler et al. [11] found visuospatial learning was
worse in those dependent on alcohol during abstin-
ence than in those who were still intoxicated. People
who experienced more alcohol withdrawal episodes
have been found to have greater subsequent memory
deficits [12]. Preclinical data also demonstrated that
withdrawal is an important factor in causing the
memory deficits. Memory and learning deficits were
found in rats in a variety of tests after alcohol withdrawal,
but not during alcohol intake [13, 14]. These data suggest
that the neurotoxicity that is known to occur during acute
alcohol withdrawal may play a contributory role in the
subsequent cognitive deficits so frequent in those who are
dependent on alcohol [15].
Benzodiazepine drugs are normally prescribed during al-
cohol detoxification to reduce the overt symptoms of alco-
hol withdrawal (tremor, and potentially fatal convulsions)
but these drugs do not prevent the longer term conse-
quences of cognitive deficits, depression, alcohol craving
and relapse back into alcohol drinking [4, 12, 16]. How-
ever, drugs that act at different target sites from that of
the benzodiazepines could have prolonged beneficial ef-
fects. The acute alcohol withdrawal phase therefore offers
a potential therapeutic window for intervention that has
previously been little explored.
There is a high level of release of glucocorticoids
(cortisol in humans, corticosterone in rodents) from
the adrenals during the acute alcohol withdrawal
period. High glucocorticoid levels are well established
to cause memory loss in both humans and animals
[17]. High circulating concentrations of cortisol and
corticosterone activate the Type II glucocorticoid receptor.
These hormones increase the neurotoxic effects of N-Me-
thyl-D-aspartate (NMDA) and other excitatory amino
acids [18]. An important link between cortisol and mem-
ory loss was found by Errico et al. [19] who showed the se-
verity of cognitive deficits in alcohol-dependent persons
was correlated not only with a greater number of with-
drawal episodes but also with higher cortisol levels during
acute withdrawal. There is also evidence relating depres-
sive symptoms and cognitive deficits [20]. Although the
direction of any potential cause/effect relationship is not
yet fully understood, glucocorticoids have been implicated
in both problems [21].
Mifepristone is an antagonist at the Type II gluco-
corticoid receptor. Administration of mifepristone to mice
during the acute phase of alcohol withdrawal was found
to reduce the subsequent memory loss [22]. Parallel
studies, using an organotypic culture model of alcohol
withdrawal, showed that high glucocorticoid concentra-
tions of glucocorticoid increased the neurotoxic conse-
quences of alcohol withdrawal. Application of the Type II
glucocorticoid receptor antagonist, mifepristone, pre-
vented this neurotoxicity [23]. In preclinical studies, mife-
pristone also reduced the behavioural signs of acute
alcohol withdrawal [23, 24]. Voluntary alcohol consump-
tion in rodents, and increases in this caused by mild stress,
were reduced by administration of mifepristone [25, 26].
Fahlke and colleagues [27, 28] showed that adminis-
tration of corticosterone increased voluntary alcohol
drinking in rats, while reduction in glucocorticoid
synthesis, or adrenalectomy, decreased alcohol intake.
Importantly for the current study, Vendroluscolo et
al. [29] showed that mifepristone reduced the increase
in operant responding for alcohol seen in alcohol-
dependent rats, without affecting responding in rats
not dependent on alcohol. In a recent clinical trial,
mifepristone was administered at 600 mg daily for
1 week to alcohol-dependent individuals who contin-
ued to drink alcohol for the first 4 days of the
treatment. Reductions in alcohol-cue craving and in
self-reported alcohol consumption were seen after
1 week of treatment, and in the latter at 1 week post
treatment [30].
Clinical studies have found mifepristone also has a
beneficial effect in depression [31–35] with a more rapid
action than conventional antidepressants [34]. A clinical
pilot study found mifepristone alleviated both the cogni-
tive deficits and the depressive symptoms in bipolar
depression [35]. However, a subsequent larger study by
the same research group found only cognitive deficits
were alleviated, specifically spatial working memory [36].
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There are no published reports of glucocorticoid an-
tagonist trials for treatment of depression in alcohol-
dependent individuals, although in some alcoholics,
conventional antidepressant drugs both alleviated depres-
sive symptoms and decreased relapse drinking [37].
Aims of the study
The current study aims to examine the extent to which the
Type II glucocorticoid receptor antagonist, mifepristone,
when given to alcohol-dependent persons during the acute
phase of alcohol withdrawal, will protect against the subse-
quent memory loss and depressive symptoms during ab-
stinence from alcohol. The results will provide information
about the extent of the contribution of glucocorticoids to
these problems, which will aid future development of
treatment for alcohol dependence.
Objectives
 To compare effects of mifepristone and placebo
in preventing memory loss and depressive
symptomatology in alcohol-dependent persons
undergoing alcohol detoxification, using the
Cambridge Neuropsychological Test Automated
battery (CANTAB) and Beck Depression Inventory
(BDI-II) [38], respectively.
 To compare effects of mifepristone and placebo
on the severity of the acute phase of alcohol
withdrawal, alcohol craving and the symptoms
of protracted withdrawal.
 To compare effectiveness of mifepristone and placebo
in maintaining abstinence from alcohol and levels of
relapse drinking at 3, 6 and 12 months follow-up
from cessation of alcohol consumption.
Methods/Design
The design of the current study is a double-blind
randomised controlled clinical trial of mifepristone
and inactive placebo. The study is a Phase 4 thera-
peutic use, “Proof of Concept” trial. Ethical approval
has been granted by the London–Dulwich Research
Ethics Committee (reference: 10/H0808/7) and complies
with UK and European Good Clinical Practice for medi-
cinal trials guidelines. Participants will be recruited from
Community Alcohol Teams serving 5 inpatient alcohol
treatment units in 3 regions of England (South London,
Sussex, Kent, Hull and Barnsley). Participants will be given
mifepristone/placebo for 2 weeks while they are in
patients undergoing detoxification from alcohol. They
will then remain in the trial for a further 2 weeks
undergoing cognitive testing and questionnaires, with
follow-up contact at 3, 6 and 12 months subsequent
to alcohol cessation.
Hypotheses
 Treatment with mifepristone will result in improved
memory and/or depressive symptomatology
outcomes compared with placebo.
 Relapse drinking rates will be reduced in those
treated with mifepristone compared with placebo.
 Activation of Type II glucocorticoid receptors
during the acute phase of alcohol withdrawal is
causally involved in the subsequent cognitive
deficits, symptoms of depression and/or relapse
drinking following acute cessation of alcohol
consumption.
Inclusion criteria
1. Diagnosis of alcohol dependence by DSM-IV for
5 years or more
2. Male
3. Aged between 18 and 60 years (inclusive)
4. Willingness to provide informed consent.
Exclusion criteria
1. Clinical diagnosis of a neuroendocrine disorder
2. Liver damage, determined at screening by alanine
aminotransferase (ALT) activity of more than
2.5 times the normal range
3. Renal dysfunction, as determined by creatinine levels
over 150 μmol/L in plasma samples taken prior to
admission to the Alcohol Unit
4. Documented evidence of a psychotic disorder
5. Severe brain damage or severe mental impairment
6. Diagnosis of severe physical illness that would
preclude participation (e.g. terminal illness),
7. Documented evidence of current dependence on a
substance other than alcohol or nicotine.
8. Inability to understand sufficient English to understand
the information needed for the cognitive testing
9. Wernicke-Korsakoff syndromes
10. Porphyria
11. Severe asthma uncontrolled by therapy
12. Cardiac disorders i.e. myocardial infarction,
congestive cardiac failure or cardiomyopathy
13. Persistent high blood pressure (over 160 mmHg
systolic and/or 100 mmHg diastolic on both of
two readings at initial screening session
14. Medical history of diabetes
15. A known allergy to mifepristone
16. Owing to potential interactions with mifepristone,
participants taking the following drugs will be
excluded unless a suitable alternative can be
prescribed: ketoconazole, itraconazole,
metronodazole, miconazole, erythromycin,
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clarithromycin, rifampin, rifabutin, norfloxacin,
nelfinavir, ritonavir, saquinavir, zafirlukast,
fluvoxamine, quinine, phenytoin, phenobarbital,
primadone, carbamazepine, amiodarone, warfarin,
corticosteroids or St John’s Wort. Consumption of
grapefruit juice is also contraindicated during the
mifepristone treatment.
Study entry
Prospective participants who are referred for an admis-
sion to an alcohol inpatient unit for alcohol detoxifica-
tion will be identified by the community alcohol teams.
If the person is willing to hear more about the research,
contact details will be passed to the research team. Writ-
ten informed consent to complete a preliminary screen-
ing appointment will be taken. Eligibility to take part in
the research will be checked at a preliminary screening
appointment and included administration of the Mini-
Mental Sate Examination (MMSE) [39] to screen for any
severe cognitive impairment. The Composite Inter-
national Diagnostic Interview (CIDI) [40] will be admin-
istered to demonstrate alcohol dependence of at least
5 years of the patients prior to detoxification according
to DSM-IV diagnostic criteria. Plasma alanine amino-
transferase (ALT) and creatinine will be measured for in-
dication of liver damage and impaired renal function,
respectively. Urine will be tested for evidence of porphy-
ria. If the participant is eligible, consent to take part in
the study will be obtained prior to or on admission to
the alcohol unit by a clinical member of the research
team or a delegated physician. All participants will be
advised not to consume grapefruit juice during the trial
as this is contraindicated with mifepristone.
At the preliminary screening appointment participants
will be asked to complete questionnaires to help estab-
lish patterns of alcohol consumption. This includes a
measure of the severity of alcohol dependence using the
Severity of Alcohol Dependence Questionnaire (SADQ)
[41], current craving for alcohol using the Alcohol Urge
Questionnaire (AUQ) [42], problems experienced due to
alcohol using the Alcohol Problems Questionnaire
(APQ) [43], and a retrospective report of the quantity of
alcohol consume over the previous 90 days collected
using the time-line follow-back (TLFB) [44]. In addition,
the Fagerstrom questionnaire [45] will be used to record
the amount of smoking and level of nicotine dependence
and symptoms of depression will be measured using the
Beck Depression Inventory (BDI-II) [46].
Randomisation and blinding
Randomisation will be carried out after consent is gained
for participation in the main trial for those participants
who are eligible. A remote randomisation procedure will
be used through an online system based at the King’s
Clinical Trials Unit at the Institute of Psychiatry, King’s
College London. This involves allocation of unique
identification numbers for each participant. The mini-
misation method will be used for the allocation that
involves stratification by severity of alcohol dependence
(SADQ score of over 40 or under 40), site and age (18 to
29, 30 to 39, 40 to 49 or 50 to 60). These variables are
known to be potential confounders with the observed
outcome and are collected at preliminary screening.
As this is a multi-centre study and allocation is blind,
those conducting the randomisation will not be in a
position to subvert the allocation sequence. The blister
packs contain 7 tablets and will be supplied in individual
cartons with a label on the front face of the carton
bearing a unique kit identification number (Kit ID). The
Kit ID is pre-printed on the label by the packaging com-
pany. Participants will be allocated Kit IDs according to
the remote randomisation procedure. Each carton sent
to the Pharmacy by the manufacturing company will be
accompanied by an individual sealed code-break envelope
in case of emergency unblinding. Participants, researchers
and ward staff will be blind to which treatment each pa-
tient is given.
Pharmacological treatment
The duration of treatment with mifepristone/placebo is
2 weeks, while participants are an inpatients in the alcohol
treatment units. The daily dose will be three 200 mg
tablets a day (morning, afternoon and evening) for 7 days
followed by two 200 mg tablets a day (morning and even-
ing). These doses are based on previous studies of the
effectiveness and toxicity of mifepristone.
The participants will receive normal clinical care while
on the unit, and concurrent medical and psychiatric disor-
ders will be treated as required. This includes prescription
of a benzodiazepine (normally chlordiazepoxide) to pro-
tect against the tremor and convulsive aspects of acute
alcohol withdrawal. Benzodiazepine treatment is normally
given to patients during the first 7 to 10 days of detoxifica-
tion, as required, and this treatment will not be altered
during the trial. All prescriptions of any drug treatment
given to trial participants will be recorded during the trial.
All participants will receive the standard care provided
by the participating alcohol treatment services. This
includes access to all the facilities provided by the
services, including psychotherapy, pharmacotherapy,
inpatient and residential rehabilitation. These services
are normally provided for up to 3 months per episode of
care. Participants who relapse or seek further treatment
will be offered additional care, in keeping with standard
clinical policies.
Assessment of efficacy
Figure 1 presents an overview of the trial protocol.
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Primary outcome measures
Cognitive ability will be measured using the CANTAB.
The CANTAB has been used extensively in research and
previous studies have been published that have used the
CANTAB test battery in patients with depression and
patients with alcohol dependence [47–52]. The CAN-
TAB testing will compare mifepristone and placebo
groups concurrently. Cognitive function measurement
prior to mifepristone/placebo would not be valid owing
to intoxication. A pretest will be carried out on the day
before the first CANTAB testing, composed of the
Motor Screening task and the Reaction time task. These
two tests are designed to assess basic motor and visual
skills and determine whether participants are capable of
being tested on CANTAB. The CANTAB tests that will
be used at the two cognition testing times (between days
13 and 20 and 21 and 28) are: visuospatial ability by Re-
action Time, Pattern Recognition, Matching to Sample
Visual Search, Spatial Recognition memory and Paired
Associates tasks; sustained attention by the Rapid Visual
Processing task; and executive function by Intra- and
Extra-Dimensional Shifting, Spatial Working Memory
and Stockings of Cambridge tasks.
The above CANTAB test times will enable examin-
ation of cognitive testing administration of chlordiaz-
epoxide ceases, as benzodiazepines are well established
to affect memory and learning. Urine samples taken on
the day of CANTAB testing will be screened for the
presence of residual chlordiazepoxide or its active me-
tabolites, which may affect cognitive performance [53].
The BDI-II [46] will be used to record symptoms of de-
pression throughout the trial. It will be administered at
every 7 days during the 4 weeks the participant is in the
trial and at 3, 6 and 12 months follow-up from cessation
of drinking. The BDI-II will be administered on the day of
the CANTAB testing so that the results can be used as a
variable in the measure of cognitive function.
Secondary outcomes
Severity of the overall syndrome of acute alcohol with-
drawal will be monitored using the Clinical Institute
Withdrawal Assessment for Alcohol (CIWA-Ar) [54].
This questionnaire will be carried out once per day for the
first week, starting 24 h after drinking cessation, as in nor-
mal clinical care, then twice every 7 days (±2 days) for the
following 2 weeks, and once during week 4.
The AUQ will be administered every 7 days, with the
first administered 24 h after drinking cessation, to meas-
ure alcohol craving. It will be administered at 3, 6 and
12 months follow-up.
Symptoms of protracted alcohol withdrawal include
anxiety, fatigue, irritability, hyperarousal and depression
[18]. The sleep questionnaire evaluates sleep distur-
bances that are a common problem during the early
Fig. 1 Trial procedure timeline
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weeks of abstinence. This questionnaire will be carried
out every 7 days (±2 days), starting 1 week after cessa-
tion of drinking and at 3, 6 and 12 months follow-up.
The Profile of mood states (POMS) [55] measures
current mood covering eight factors: anxiety, fatigue,
depression, anger, vigour, confusion, friendliness and
elation. The POMS will be carried out every 7 days
(±2 days), starting 1 week after drinking cessation and at
3, 6 and 12 month follow-up. The Snaith Hamilton
Pleasure Scale (SHAPS) [56] is designed to assess an in-
dividual’s ability to experience pleasure. The SHAPS will
be carried out on days 7, 14, 21, 28 (±2 days) and at 3, 6
and 12 month follow-up after cessation of drinking.
A maximum of 21 saliva samples will be collected
from each participant during the trial. Seven saliva sam-
ples will be collected during the course of the day on
three different occasions (day 2, 7 and 20 ± 2 days after
cessation of alcohol drinking). Samples will be collected in
prepared tubes and were analysed for cortisol concentra-
tions to determine the cortisol levels prior to and follow-
ing mifepristone or placebo treatment. Saliva samples will
only be collected while participants are in-patients; saliva
sample collection will not be taken from participants who
are out-patients.
Maintenance of abstinence from alcohol and levels of
relapse drinking will be measured using the TLFB,
administered at preliminary screening and at 3, 6 and
12 months follow-up after cessation of drinking.
Assessment of safety
The procedures involved in this research are unlikely to
cause significant discomfort or distress to participants.
All questionnaire measures and research procedures
have been widely validated and used in previous research
without causing any problems to participants. Mifepris-
tone has a good safety record and has been used clinic-
ally for over 15 years for other applications. However
should any distress or discomfort occur with any of the
procedures trained medical and nursing staff will be
available on a 24 h basis to provide help and support.
All staff involved in the care of trial participants will
receive training on the conduct of the trial protocol. In
particular training will be provided on the detection and
management of expected and unexpected adverse drug
events.
The collection and reporting of Adverse Events will
start following the first dose of the trial medication and
will continue until the last dose of the trial medication.
Reporting of Serious Adverse Events, Serious Adverse
Reactions and Suspected Unexpected Serious Adverse
Reactions will continue until 14 days after stopping the
trial medication. All concomitant medications will be re-
corded until 14 days after stopping the trial medication.
Daily assessments by the clinical team to monitor for
signs of nausea or fatigue that might indicate adrenal
insufficiency will be made. Analysis of the plasma
samples that will be taken on days 1, 7 and 14 of the
mifepristone/placebo administration will ensure that the
electrolyte levels remain within normal limits (sodium
135–145, potassium 3.5–5.3, chloride 95–105, urea 3.3–
6.7, creatinine 40–120, all units micromoles per litre).
Blood pressure checks were carried out daily during the
acute withdrawal phase (10–14 days) as part of the normal
clinical routine, and on day 14 if not measured on that
day as part of normal clinical care. In the event of a par-
ticipant self-discharging from the unit before the course
of mifepristone is completed, the mifepristone/placebo
treatment will be stopped and the participant will be
withdrawn from the trial.
Following recruitment of the first 20 participants the
Data Monitoring Committee will carry out a detailed
examination of the safely data to ensure that there no
problems have arisen with regard to drug safety.
Honorarium
A £10 voucher for a local store that cannot be used to
buy alcohol, will be given after completion of prelimin-
ary screening, on each of the 2 days of completion of the
CANTAB testing plus a further voucher on completion
of the follow-up contacts.
Sample size
As this is a Proof of Concept study, previous data on the
target population was not available. However, previously
published studies using the CANTAB test battery in
depressed patients have shown effect sizes of 0.5, 0.8,
0.76 [48], 0.496, 0.5 [51], 0.897 [49] and, 0.7 for spatial
working memory in the elderly [50]. Similar values were
obtained studying effects of acute alcohol withdrawal
using an early version of the CANTAB [52]. We esti-
mated the numbers needed in each group for a variety
of effect size estimates based on a power of 80 % and
alpha of 0.05. For an effect size difference of 0.8 25 sub-
jects per group would be required and this increased to
32 for an effect size difference of 0.7 and 63 if the differ-
ence was 0.5. As a proof of principle study we erred on
the side of caution and aimed to detect a small to
medium effect size of 0.5 and this required 120 subjects
participating in the study.
Statistical analysis
The null hypothesis is that there will be no differences
in the results from the cognitive testing between partici-
pants who received mifepristone and those who received
the placebo. Primary data analysis will be by analysis of
variance (ANOVA) on the CANTAB results and Beck
depression scale scores for mifepristone and placebo
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groups, with post hoc tests for variables likely to affect
these results. Analysis will be carried out both on a per
protocol basis and an intention to treat basis.
A repeated measures analysis of variance using
treatment type as a between-subject factor (two levels:
mifepristone and placebo) and number of times the scale
is applied as the within-subjects factor (five levels) will
be carried out on the Beck depression scale results. This
analysis will examine changes in level of depressive
symptoms over the 4 weeks of the study. The analysis
on the results from the BDI-II will compare the depres-
sive symptoms prior to mifepristone/placebo with the
scores during the four test weeks. This will provide
information about whether or not mifepristone alters
the progression of such symptoms and enable effect
sizes to be calculated for such multiple comparisons in a
full trial.
Cognitive performance
Reliable estimates of potential effects and variances will
be obtained which will enable such repeated analysis in
future, full clinical, trials (repeated measures analyses
will not possible in this initial Proof of Concept study, as
there will be insufficient information on between and
within group variances).
Post hoc analysis
Although participants in the two treatment groups will
be balanced, potential confounds will be examined as co-
variates in the post hoc ANCOVA analysis. Covariates
will include: severity of withdrawal symptoms (measured
by the CIWA-Ar, which primarily examines autonomic
symptoms, and the AUQ which measures alcohol crav-
ing); presence/absence of depressive symptoms; smoking/
non-smoking, chlordiazepoxide dosage; other medication
prescribed after detoxification; co-morbid psychiatric dis-
orders other than depression, other medication and age.
Data management
Data will be anonymised and be stored by secure means.
Electronic data will be stored on password protected
computers or laptops. Hard copy data will be stored in
locked filing cabinets in lockable offices in buildings with
swipe access and security presence. All data will be
entered into a computerised data entry system at King’s
College London. At the end of the study arrangements
will be made with the appropriate data repository service
for transfer and preservation of the data in accordance
with the principles agreed by the NHS and the MRC for
the preservation and sharing of clinical data.
The results from the CANTAB cognition testing have
to be entered directly on to a laptop as this is an integral
part of this testing. Immediately at the end of each test
session, the data entered on the laptop will be encrypted
using a file encryption key to which only the research
team will have access. No personal data will be entered
on the laptop; the data will be stored under code num-
bers so that individual participants cannot be identified.
As soon as possible after the end of a test session the
data will be transferred to a secure server at King’s
College London and the data erased from the laptop.
In order that contact can be made for the follow-up
interviews, identifiable patient information will be
accessed by the research team from the medical notes,
with the patient’s consent. No personal information will
be stored with the trial data.
Arrangements will be made for a copy of all the original
data to be “locked” electronically prior to the analysis and
kept at King’s College London in a secure location so that
a record will be available of all the original results. The
data will also be stored on the computer data system for
archiving at the end of the study.
The investigators and Institution will permit trial-
related monitoring, audits, Research Ethics Committee
and Research and Development department review and
regulatory inspections by providing direct access to
source data and other documents (results of cognitive
testing, depression scales, blood, saliva and urine test
reports) and data analysis results.
Monitoring
An independent Steering Committee has been set up,
chaired by Professor Nicol Ferrier, Newcastle University.
Members: Professor Anne Lingford Hughes, Imperial
College and Professor Theodora Duka, Sussex Univer-
sity. The Medical Research Council has approved this
membership. A Data Monitoring Committee has been
set up and includes a statistician who is not otherwise
involved in the project. A project management group
will meet regularly to monitor the progress of the trial.
This group will include the Chief Investigator, the
Principal Co-Investigators, the researchers and clinicians
and user representative. The trial will also be monitored
in accordance with the King’s Health Partners Clinical
Trials Office Quality Policy.
Discussion
Preclinical trials have suggested that Type II glucocortic-
oid receptor activation during acute alcohol withdrawal
is related to impairment of cognitive function. Treat-
ment with mifepristone, a Type II glucocorticoid recep-
tor antagonist, may protect against this. Clinical studies
have shown that mifepristone has a beneficial effect in
depression. The MIFCOG study is the first clinical trial
to examine the role of glucocorticoid receptor activation
in cognitive function and depression during protracted
alcohol withdrawal, and the efficacy of treatment with
mifepristone.
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Trial status
Recruitment for the trial began in September 2012 and
was completed in May 2015. A total of 26 participants
were recruited between September 2012 and September
2014. The trial experienced several challenges in recruit-
ment over this 2 year period including retendering of NHS
addiction services and the closure of NHS specialist addic-
tion units at participating research sites. In September
2014 the decision was made to recruit participants who
were completing their detoxification as an outpatients as
well as an inpatients, to increase the number of potential
participants. This decision was made following advice from
the Trial Steering Committee and the Data Monitoring
Committee and the results of the safety report following
recruitment of the first 20 participants. Approval from the
MHRA and local Research Ethics Committee to recruit
participants completing their detoxification as outpatients
was granted in November 2014. The study protocol was
largely unchanged for outpatient recruitment, with the
following exceptions;
1. Saliva sample collection was removed as it was not
possible to gain reliable waking samples if
participants were not an inpatient.
2. CIWA assessments were only completed for days
2–5 as there were insufficient staffing resources to
complete these assessments at a weekend.
3. Plasma samples taken on days 7 and 14 were taken
on days 7 and 14 +/− 2 days to allow for times
when they fell on a weekend.
Following approval to recruit participants completing
their detoxification as outpatients as well as those com-
pleting a detox as inpatients only 1 further participant was
recruited. Completion of the final 12 month follow-up will
be completed in May 2016.
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